BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 21617235)

  • 1. Pemetrexed-induced hyperpigmentation of the skin.
    Schallier D; Decoster L; de Greve J
    Anticancer Res; 2011 May; 31(5):1753-5. PubMed ID: 21617235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pemetrexed-induced lung toxicity: a case report.
    Breuer S; Nechushtan H
    Clin Oncol (R Coll Radiol); 2012 Feb; 24(1):76-7. PubMed ID: 21924594
    [No Abstract]   [Full Text] [Related]  

  • 3. [Study of use of pemetrexed in non-small cell lung cancer].
    Villanueva-Herraiz S; Ortega-García MP; Camps-Herrero C; Blasco-Segura P
    Farm Hosp; 2010; 34(4):194-203. PubMed ID: 20594885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pemetrexed induced aseptic meningitis.
    Shah BK; O'Keefe S
    Acta Oncol; 2012 Mar; 51(3):399-400. PubMed ID: 21936754
    [No Abstract]   [Full Text] [Related]  

  • 5. Pemetrexed and maintenance therapy for non-small cell lung cancer.
    Prescrire Int; 2011 Feb; 20(113):39. PubMed ID: 21488588
    [No Abstract]   [Full Text] [Related]  

  • 6. Interstitial pneumonitis after treatment with pemetrexed: a rare event?
    Hochstrasser A; Benz G; Joerger M; Templeton A; Brutsche M; Früh M
    Chemotherapy; 2012; 58(1):84-8. PubMed ID: 22377772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.
    Sun JM; Lee KW; Kim JH; Kim YJ; Yoon HI; Lee JH; Lee CT; Lee JS
    Jpn J Clin Oncol; 2009 Jan; 39(1):27-32. PubMed ID: 18952704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case of pemetrexed-induced acute lung injury in non-small cell lung cancer.
    Kim HO; Lee SY; Shim JJ; Kang KH; Shin BK
    J Thorac Oncol; 2010 Mar; 5(3):401-2. PubMed ID: 20186027
    [No Abstract]   [Full Text] [Related]  

  • 9. Pemetrexed-induced cellulitis: a rare toxicity in non-small cell lung cancer treatment.
    Katsenos S; Psara A; Panagou C
    J Oncol Pharm Pract; 2013 Mar; 19(1):93-4. PubMed ID: 22357637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pemetrexed in first-line treatment of non-small cell lung cancer.
    Esteban E; Casillas M; Cassinello A
    Cancer Treat Rev; 2009 Jun; 35(4):364-73. PubMed ID: 19269106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute generalized exanthematous pustulosis after pemetrexed, and recurrence after re-introduction.
    Bracke A; Van Marck E; Lambert J
    Clin Exp Dermatol; 2009 Apr; 34(3):337-9. PubMed ID: 18699838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Safety of pemetrexed mono-therapy in elderly patients with non-small cell lung cancer].
    Konishi A; Kitada N; Nanjo S; Tanaka S; Tomii K; Katakami N; Hashida T
    Gan To Kagaku Ryoho; 2012 Oct; 39(10):1507-10. PubMed ID: 23064061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Management and maintenance of pemetrexed monotherapy regimen - initial experience of pretreated non-small cell lung cancer].
    Takase M; Maruoka H; Ametani F; Takahashi M; Shibata K
    Gan To Kagaku Ryoho; 2012 Apr; 39(4):563-5. PubMed ID: 22504678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe immune hemolytic anemia due to pemetrexed in a patient with non-small cell lung cancer.
    Sun X; Sheng L; Deng Q; Liu P; Lu K
    Pharmacology; 2011; 88(5-6):242-4. PubMed ID: 21997597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pemetrexed-induced edema of the eyelid.
    Kurata T; Tamura K; Okamoto I; Satoh T; Nakagawa K; Fukuoka M
    Lung Cancer; 2006 Nov; 54(2):241-2. PubMed ID: 16996165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pemetrexed: new indication. Untreated non-small cell lung cancer: just another cytotoxic drug. No better than the gemcitabine-cisplatin combination with a different safety profile, as is the case for other cytotoxic drugs.
    Prescrire Int; 2009 Jun; 18(101):114. PubMed ID: 19637425
    [No Abstract]   [Full Text] [Related]  

  • 17. Toxic epidermal necrolysis related to pemetrexed and carboplatin with vitamin B12 and folic acid supplementation for advanced non-small cell lung cancer.
    Bosch-Barrera J; Gaztañaga M; Ceballos J; Pérez-Gracia JL; López-Picazo JM; García-Foncillas J; Ferrer M; Sanz ML; Pretel M; Idoate MA; Gil-Bazo I
    Onkologie; 2009 Oct; 32(10):580-4. PubMed ID: 19816075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Typhlitis during second-line chemotherapy with pemetrexed in non-small cell lung cancer (NSCLC): A case report.
    Tiseo M; Gelsomino F; Bartolotti M; Barili MP; Ardizzoni A
    Lung Cancer; 2009 Aug; 65(2):251-3. PubMed ID: 19346026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-escalation study of pemetrexed in combination with carboplatin followed by pemetrexed maintenance therapy for advanced non-small cell lung cancer.
    Okamoto I; Takeda K; Daga H; Miyazaki M; Yonesaka K; Kiyota H; Tsurutani J; Ueda S; Ichikawa Y; Takeda M; Sekiguchi R; Tominaga K; Enatsu S; Nambu Y; Nakagawa K
    Lung Cancer; 2010 Nov; 70(2):168-73. PubMed ID: 20236726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed-induced radiation recall dermatitis of the breast.
    Boesmans S; Decoster L; Schallier D
    Anticancer Res; 2014 Mar; 34(3):1179-82. PubMed ID: 24596357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.